Geode Capital Management LLC Has $223,000 Holdings in GeoVax Labs, Inc. (NASDAQ:GOVX)

Geode Capital Management LLC grew its holdings in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) by 59.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 90,139 shares of the company’s stock after purchasing an additional 33,440 shares during the quarter. Geode Capital Management LLC owned about 0.95% of GeoVax Labs worth $223,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Virtu Financial LLC acquired a new stake in shares of GeoVax Labs in the third quarter worth $97,000. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

GeoVax Labs Trading Up 2.1 %

Shares of NASDAQ:GOVX opened at $1.01 on Friday. The firm has a market capitalization of $13.98 million, a PE ratio of -0.18 and a beta of 3.70. GeoVax Labs, Inc. has a 1-year low of $0.73 and a 1-year high of $11.18. The business’s 50 day moving average is $1.21 and its 200-day moving average is $1.86.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.14. The business had revenue of $1.64 million for the quarter, compared to analyst estimates of $0.75 million. On average, sell-side analysts predict that GeoVax Labs, Inc. will post -4.49 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Alliance Global Partners cut their price objective on GeoVax Labs from $15.00 to $8.50 and set a “buy” rating for the company in a research report on Tuesday, April 15th. D. Boral Capital cut their price target on GeoVax Labs from $14.00 to $9.00 and set a “buy” rating for the company in a report on Friday. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a research note on Wednesday, April 16th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $11.10.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.